Search Results
Your search for ,are matches 21909 pages
Showing 2601 - 2650Does Colon Tumor Location Play a Role in Metastasis and Survival?
There have been demonstrated differences in tumor cell metabolism between right-sided and left-sided colorectal tumors, which could explain the differences observed in their clinical behavior, especially in metastatic disease. Now, new research has found that patients with right-sided colorectal...
Mutations in 11 Genes May Be Associated With Aggressive Prostate Cancer
Researchers have singled out mutations in 11 genes associated with aggressive types of prostate cancer, according to a novel study published by Darst et al in JAMA Oncology. The new findings may lead to improvements in diagnosis and treatment. Background Currently, oncologists use genetic tests to...
Annual Report to the Nation on the Status of Cancer, Part 2, Focuses on COVID-19’s Impact on Cancer Diagnoses
The Annual Report to the Nation on the Status of Cancer, Part 2—published by Negoita et al in the journal Cancer—showed that new diagnoses of six major cancer types in the United States fell sharply between March and May of 2020, coinciding with the beginning of the COVID-19 pandemic. The six...
FDA Approves Bosutinib for Pediatric Patients With Chronic Myelogenous Leukemia
On September 26, the U.S. Food and Drug Administration (FDA) approved bosutinib (Bosulif) for pediatric patients aged 1 year and older with chronic-phase, Philadelphia chromosome–positive chronic myelogenous leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. The FDA ...
Gynecologic Cancer Misinformation May Be Widespread on TikTok
The majority of information related to gynecologic cancers on the social media platform TikTok may be misleading or inaccurate, according to a recent study published by Morton et al in Gynecologic Oncology. Background “The intent of this study was to understand the needs of patients that may go...
Oral Health May Be Linked to Survival in Patients With Head and Neck Squamous Cell Carcinoma
Investigators have revealed that oral health may be associated with survival in patients with head and neck squamous cell carcinoma, according to a novel study published by Tasoulas et al in the Journal of the National Cancer Institute. Background While survival has improved during the past decades ...
Management of De Novo Metastatic Estrogen Receptor–Positive Breast Cancer
This is Part 3 of Ovarian Function Suppression in Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Jame Abraham, Erin Roesch, and Azka Ali discuss the management of a patient with de novo metastatic estrogen...
Do Checkpoint Inhibitors Show Benefit in EGFR-Mutated NSCLC After Progression?
In patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations, the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 ...
High-Intensity Training May Reduce the Risk of Colorectal Cancer in Patients With Lynch Syndrome
Regular and intense aerobic exercise may be effective at reducing the risk of colorectal cancer in patients with Lynch syndrome by improving the immune system's ability to detect and remove potentially harmful cells, according to a novel study published by Deng et al in Clinical Cancer Research....
Exposure to PFAS and Phenols May Be Linked to Cancer Risk
Investigators have discovered that significantly higher levels of endocrine-disrupting chemicals such as per- and poly-fluoroalkyl substances (PFAS) and phenols may be present in patients with breast, ovarian, skin, and endometrial cancers, according to a recent study published by Cathey et al in...
MD Anderson and Ochsner Health Partner to Create First Fully Integrated Cancer Program in Louisiana
The University of Texas MD Anderson Cancer Center and New Orleans–based Ochsner Health recently announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Patients with cancer in the region now will have access to treatments that are among the most advanced in...
City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies
Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine (CIRM) to support three novel phase I clinical trials evaluating innovative cell and gene therapies for patients with HIV, acute myeloid leukemia (AML), and severe aplastic anemia. Beckman ...
Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma
The management of sarcoma presents several challenges because of its rarity and diverse subtypes, making accurate diagnosis and specialized treatment crucial. A multidisciplinary approach involving various experts from different cancer specialties is the optimal strategy to improve survival and...
Finding a New Life Purpose After Cancer
In the summer of 2012, I was living my dream. At 28 years old, I had gone from an impoverished childhood in South Central Los Angeles to the high life in the city of Los Angeles. Unable to afford to go to college, an after-school program helped launch me into a career in the hospitality industry. I ...
Surgical Oncologist Héber Salvador, MD, PhD, Offers an Inside Look at Cancer Care in Brazil, Complete With Its Diversity and Inequities
In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, the Jerald L. & Carolynn J. Varner Professor of Surgical Oncology & Global Health at the University of Nebraska Medical Center, Omaha, spoke with Héber Salvador, MD, PhD,...
ACS Funds UAMS Study to Understand Treatment Resistance in Pancreatic Cancer
Adam Wolfe, MD, PhD, a radiation oncologist at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute, has received a $583,200 grant from the American Cancer Society (ACS) to study radiation resistance in pancreatic cancer, a lethal disease with the highest...
From Texas to Sweden, Medical Oncologist Gil Morgan, MD, Enjoys Connecting the Cancer Community
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Gil Morgan, MD, a clinical oncologist formerly at the Division of Medical and Radiation Oncology at Skåne University Hospital, Lund, Sweden and now full-time Director of the OncoAlert...
Particulate Matter Concentrations and Incidence of Breast Cancer
Investigators have found that residing in areas with high levels of particulate air pollution may be associated with an increased risk of developing breast cancer, according to a recent study published by White et al in the Journal of the National Cancer Institute. Background Particulate matter...
Lung-MAP Study May Improve Access to Clinical Trials for Underrepresented Patients
The biomarker-driven Lung Cancer Master Protocol (Lung-MAP) may have enrolled a higher percentage of patients who are older, are from rural or socioeconomically deprived areas, and have Medicaid or no insurance compared with conventional, standalone clinical trials in advanced non–small cell lung...
Magrolimab Plus Azacitidine in Previously Untreated Patients With AML Ineligible for Intensive Chemotherapy
In a phase Ib study reported in the Journal of Clinical Oncology, Naval G. Daver, MD, and colleagues found that the combination of the anti-CD47 antibody magrolimab and azacitidine was active in previously untreated patients with acute myeloid leukemia (AML) who were ineligible for intensive...
SIO and ASCO Partner to Develop Integrative Oncology Care Recommendations for Anxiety and Depression in Patients With Cancer
The Society for Integrative Oncology (SIO) and ASCO have partnered to develop a new guideline on integrative oncology care of symptoms of anxiety and depression in adults with cancer. The guideline reviews the evidence for a range of integrative approaches, including mindfulness-based...
ASCO Participates in President’s Cancer Panel
ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...
ASTRO Names FASTRO Recipients for 2023
A total of 29 distinguished members of the American Society for Radiation Oncology (ASTRO) have been named Fellows of ASTRO. The ASTRO Fellow designation, FASTRO, honors individuals who have contributed significantly to the Society through committee work, other volunteer service, and to the field...
Ipilimumab Plus Nivolumab May Improve Outcomes in Refractory Metastatic Melanoma, Study Suggests
Researchers have discovered that the combination of the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent study conducted by the SWOG Cancer Research Network and...
More on Biliary Tract Cancer From ASCO 2023: Focus on Zanidatamab
The HER2-targeting bispecific antibody zanidatamab generated rapid and durable responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer previously treated with gemcitabine, investigators from the global phase IIb HERIZON-BTC-01 study reported at...
Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting
The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...
Understanding the Treatment of Waldenström’s Macroglobulinemia
Waldenström’s macroglobulinemia is a rare and incurable low-grade B-cell lymphoproliferative disease defined by specific genotypic subtypes that have implications for treatment response and long-term outcomes. Treatment—and there is no established standard—is mainly focused on controlling symptoms...
Distributing Scarce Cancer Drugs Legally and Ethically
During the COVID-19 pandemic, many medical specialties became familiar with supply chain interruptions resulting in drug, equipment, and personnel scarcity. Intensive care unit beds, staff, and essential medicines were at times in short supply. The federal government, individual states, and...
NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC
The anti–PD-L1 monoclonal antibody durvalumab in combination with other immuno-oncology agents may outperform treatment with durvalumab alone in the neoadjuvant setting for patients with early-stage non–small cell lung cancer (NSCLC), according to a recent study published by Cascone et al in Cancer ...
Accelerating Progress Against Cancer and Other Life-Threatening Diseases
Cancer—and the quest to accelerate more effective treatments and potential cures for all life-threatening diseases—has perhaps shaped the life of financier Michael Milken more than his legendary career on Wall Street. In the early 1970s, Mr. Milken’s mother-in-law was diagnosed with metastatic...
The Immune System May Play Vital Role in Remission Duration Among Patients With Multiple Myeloma
Researchers have uncovered the vital role that the immune system may play in determining the duration of remission and progression-free survival in patients with multiple myeloma, according to a recent study published by Coffey et al in Nature Communications. The new findings suggested that the...
First-Line Pembrolizumab Plus Lenvatinib Active in Advanced Non–Clear Cell Renal Cell Carcinoma
In a phase II trial (KEYNOTE-B61) reported in The Lancet Oncology, Laurence Albiges, MD, PhD, of Gustave Roussy, Paris–Saclay University, Villejuif, France, and colleagues found that first-line pembrolizumab plus lenvatinib produced durable responses in patients with advanced non–clear cell renal...
Colorectal Cancer Screening: Major Communication Gap in the Clinical Setting
According to the American Cancer Society, colorectal cancer is the second-leading cause of cancer-related death in the United States. In 2023, the disease is expected to cause an estimated 52,550 deaths. Studies show that receiving a clinician recommendation is the strongest and most consistent...
Addition of Olaparib to Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Overall Survival Results in the PROpel Trial
As reported by Fred Saad, MD, and colleagues in The Lancet Oncology, the final prespecified overall survival analysis of the phase III PROpel trial showed no significant benefit with the addition of first-line olaparib to abiraterone in patients with metastatic castration-resistant prostate cancer...
PSA Screening for HIM Act Introduced in Senate; Aims to Reduce Costs for Prostate Cancer Screening
Bipartisan legislation that may help to eliminate financial barriers to prostate cancer screening was introduced in the U.S. Senate. Sponsored by Senators Cory Booker (D-NJ) and John Boozman (R-AR), the Prostate-Specific Antigen Screening for High-Risk Insured Men (PSA Screening for HIM) Act would...
Reproductive Factors May Be Associated With Higher Risk of Lung Cancer in Women
Investigators have discovered that women with certain reproductive factors may have an elevated risk of developing lung cancer, according to recent findings presented by Zhang et al at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (Abstract...
LungCAN Advocacy Program Nets 25% Increase in LCRP Funding
The Lung Cancer Action Network (LungCAN) advocacy program may have helped increase funding for the U.S. Department of Defense Congressionally Directed Medical Research Program/Lung Cancer Research Program (LCRP) by 25%, according to recent findings presented by Donaldson et al at the International...
Retrospective Study Reports Tyrosine Kinase Inhibitor Used in CML Associated With Nephrotoxicity
Investigators reported that the tyrosine kinase inhibitor dasatinib, commonly used to treat chronic myeloid leukemia (CML), was associated with nephrotoxicity in 10% of 32 patients with CML being treated with dasatinib in a multicenter, retrospective clinical study conducted to determine the...
ctDNA Identified in Breast Milk From Women With Breast Cancer
Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum may contain circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in ...
Study Examines Disparities in Access to Cancer Care Among Non–English-Speaking Patients in the United States
Researchers have revealed that non–English speakers who seek information from hospitals across the United States may face a concerning lack of access to cancer care services, according to a new study published by Chen et al in JNCCN–Journal of the National Comprehensive Cancer Network. Background...
FDA Approves Momelotinib for Patients With Myelofibrosis and Anemia
On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post–polycythemia vera and post–essential thrombocythemia), in adults with anemia....
Decentralized Care Models Empower Equitable Pediatric Cancer Treatment
Childhood Cancer Awareness Month is recognized every September to help shine a light on the realities of pediatric cancer and raise awareness of the important work being done to make a difference for the children who are diagnosed with cancer. September 15 also marked the start of Hispanic Heritage ...
Accuracy of IASLC's 2009 Database for Pleural Mesothelioma Staging
Researchers have validated the accuracy of the International Association for the Study of Lung Cancer’s (IASLC) 2009 pleural mesothelioma database, with these findings presented by Wolf et al at the IASLC 2023 World Conference on Lung Cancer (Abstract MA17.04). Background Pleural mesothelioma often ...
Comparing Radiation Therapies for NSCLC
Intensity-modulated radiation therapy may be the preferred treatment option for patients with locally advanced non–small cell lung cancer (NSCLC), according to findings presented by Chun et al at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer ...
Extensive-Stage Small Cell Lung Cancer: Triplet Combination vs Chemotherapy Alone
The combination of benmelstobart, anlotinib, and chemotherapy may be effective at improving median progression-free survival and overall survival in patients with extensive-stage small cell lung cancer compared with placebo and chemotherapy, according to findings presented by Cheng et al at the...
AACR Issues Annual Cancer Progress Report
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in cancer prevention and early detection, has led to a 33% reduction in cancer...
Decentralized Care Models Empower Equitable Pediatric Cancer Treatment
Childhood Cancer Awareness Month is recognized every September to help shine a light on the realities of pediatric cancer and raise awareness of the important work being done to make a difference for the children who are diagnosed with cancer. September 15 also marked the start of Hispanic Heritage ...
Is Adagrasib Active in KRAS G12C–Mutated NSCLC?
The oral KRAS G12C inhibitor adagrasib may offer durable clinical activity, with a median overall survival of 14.1 months and a 2-year survival rate of about 33%, in patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to findings presented by Gadgeel et al at the...
FDA Approves New, Updated Indications for Temozolomide
On September 14, the U.S. Food and Drug Administration (FDA) approved updated labeling for temozolomide (Temodar) for the treatment of CNS cancers under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for older oncology drugs to ensure information ...
Quarterback Trial: De-escalation of Chemoradiotherapy for Subset of Patients With HPV-Positive Oropharyngeal Cancer
De-escalation of chemoradiotherapy after induction chemotherapy yields excellent oncologic outcomes in patients with high-risk oropharyngeal cancer associated with the human papillomavirus (HPV). Results of the nonrandomized phase II Quarterback trial suggest that this subset of patients may be...
